levetiracetam

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Idiopathic Axonal Polyneuropathy

Conditions

Chronic Idiopathic Axonal Polyneuropathy

Trial Timeline

Aug 1, 2005 → May 1, 2007

NCT ID

NCT00156689

About levetiracetam

levetiracetam is a phase 2 stage product being developed by UCB for Chronic Idiopathic Axonal Polyneuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00156689. Target conditions include Chronic Idiopathic Axonal Polyneuropathy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03340064	Phase 3	Completed	Nov 30, 2017	Jul 28, 2023	Partial Seizures
NCT01618877	Phase 1	Completed	May 1, 2012	Jul 1, 2012	Human Volunteers
NCT01407523	Phase 2	Completed	Jul 1, 2011	Feb 1, 2012	Epilepsy
NCT01398956	Phase 3	Completed	Jun 1, 2011	Apr 1, 2016	Epilepsy
NCT01292837	Phase 3	Completed	Feb 1, 2011	Jun 1, 2013	Epilepsy
NCT01063764	Phase 3	Completed	Jan 1, 2010	Oct 1, 2013	Epilepsy
NCT00505934	Phase 2	Completed	May 1, 2008	Mar 1, 2010	Epilepsy
NCT00627133	Phase 2	Withdrawn	Feb 1, 2008	—	Seizure, Alcohol Related
NCT00535392	Phase 2	Completed	Sep 1, 2007	Feb 1, 2010	Epilepsy
NCT00376766	Phase 3	Terminated	Feb 1, 2007	Apr 1, 2008	Epilepsy
NCT00361010	Pre-clinical	Completed	Dec 1, 2006	Dec 1, 2007	Epilepsy
NCT01318408	Approved	Completed	Nov 1, 2006	Mar 1, 2008	Epilepsy
NCT00367432	Phase 3	Completed	Jul 1, 2006	Dec 1, 2010	Epilepsies
NCT00291655	Phase 3	Completed	Jun 1, 2006	Apr 1, 2008	Epilepsy
NCT00324454	Phase 2	Completed	May 1, 2006	Jun 1, 2008	Motor Neuron Disease
NCT00319605	Pre-clinical	Completed	Apr 1, 2006	Jul 1, 2006	Epilepsy
NCT00307450	Approved	Completed	Mar 1, 2006	Jul 1, 2009	Parkinson's Disease
NCT00279617	Phase 3	Completed	Jan 1, 2006	Mar 1, 2009	Panic Disorder
NCT00325182	Approved	Completed	Jan 1, 2006	Oct 1, 2009	Alcoholism
NCT00252954	Approved	Completed	Nov 1, 2005	Dec 1, 2008	Injuries, Spinal Cord

Competing Products

20 competing products in Chronic Idiopathic Axonal Polyneuropathy

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from UCB

LevetiracetamApproved

Parcopa + carbidopa-levodopa (Sinemet)Approved

LevocetirizineApproved

RotigotineApproved

Levetiracetam + OxcarbazepineApproved